Treatment of Intrapartum Depression Using Non-invasive Photobiomodulation

Status unconfirmed · Not applicable · Has a placebo group

Conditions studied: Depression, Pregnancy Related, Intrapartum Depression

In brief

Depression during pregnancy can cause fetal and maternal problems such as growth restriction, preterm labor, low birthweight, poor compliance and suicide. Since antidepressant medications have the potential to harm the baby, but since treatment of intrapartum depression is essential to maternal and fetal wellbeing, a non-pharmacological approach would be ideal. This project seeks to apply infrared light noninvasively to depressed patients during pregnancy in order to treat depressive symptoms through alteration of mitochondrial function and modulation of neural cell receptors.

Key facts

Study ID

NCT04404231

Run by

Wayne State University

People needed

80

Starts

2021-11-01

Expected to finish

2022-09-01

Last updated by the study team

2021-10-05

Who can join

Age: 18 and older, up to 45. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Viable intrauterine pregnancy <16 weeks, PHQ-9 or Edinburg Score>10.

You may not qualify if…

• pregnancy > 20 weeks
• history of seizures
• history of migraines
• history of multiple sclerosis
• prior traumatic brain injury
• prior history of preeclampsia/toxemia
• elevated blood pressure greater than 140/90
• proteinuria (as defined by urine proteins >300 mg/24 h)
• headaches
• visual changes
• right upper quadrant pain
• history of bipolar disease
• currently taking psychotropic medications (including antidepressants) and
• prior history of attempted suicide

Where it is running

• Detroit Medical Ceter — Detroit, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.